Ritonavir or saquinavir impairs the invasion of cervical intraepithelial neoplasia cells via a reduction of MMP expression and activity

AIDS

Volumn 26, Issue 8, 2012, Pages 909-919

  Barillari, Giovanni ^a,b   Iovane, André ^a,b   Bacigalupo, Ilaria ^a   Palladino, Clelia ^a   Bellino, Stefania ^a   Leone, Patrizia ^a   Monini, Paolo ^a   Ensoli, Barbara ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

cervical carcinoma; cervical intraepithelial neoplasia; HIV protease inhibitors; matrix metalloproteinases; neoplasm invasion

Indexed keywords

GELATINASE A; GELATINASE B; INDINAVIR; MATRIX METALLOPROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CAUSE OF DEATH; CELL INVASION; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; ZYMOGRAPHY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; EPITHELIAL CELLS; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; RITONAVIR; SAQUINAVIR; UTERINE CERVICAL NEOPLASMS;

EID: 84861035150     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328351f7a5     Document Type: Article

References (57)

1. Lehoux M, D'Abramo CM, Archambault J. Molecular mechanisms of human papillomavirus-induced carcinogenesis. Public Health Genomics 2009; 12:268-280.
2. Monk BJ, Willmott LJ, Sumner DA. Antiangiogenesis agents in metastatic or recurrent cervical cancer. Gynecol Oncol 2010; 116:181-186.
3. Sheu BC, Lien HC, Ho HN, Lin HH, Chow SN, Huang SC, et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 2003; 63:6537-6542.
4. Argüello-Ramírez J, Pérez-Cárdenas E, Delgado-Chávez R, Solorza-Luna G, Villa-Trevino S, Arenas-Huertero F. Matrix metalloproteinases-2, -3, and -9 secreted by explants of benign and malignant lesions of the uterine cervix. Int J Gynecol Cancer 2004; 14:333-340.
5. Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Weis B, et al. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 1999; 72: 380-386.
6. Nasr M, Ayyad SB, El-Lamie IK, Mikhail MY. Expression of matrix metalloproteinase-2 in preinvasive and invasive carcinoma of the uterine cervix. Gynaecol Oncol 2005; 26:199-2002.
7. Talvensaari-Mattila A, Turpeenniemi-Hujanen T. Matrix metalloproteinase 9 in the uterine cervix during tumor progression. Int J Gynaecol Obstet 2006; 92:83-84.
8. Yang SF, Wang PH, Lin LY, Ko JL, Chen GD, Yang JS, et al. A significant elevation of plasma level of matrix metalloproteinase-9 in patients with high-grade intraepithelial neoplasia and early squamous cell carcinoma of the uterine cervix. Reprod Sci 2007; 14:710-718.
9. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123: 187-194.
10. Soncini E, Zoncada A, Condemi V, Antoni AD, Bocchialini E, Soregotti P. Reduction of the risk of cervical intraepithelial neoplasia in HIV-infected women treated with highly active antiretroviral therapy. Acta Biomed 2007; 78:36-40.
11. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998; 12:1459-1464.
12. Sellors J, Lewis K, Kidula N, Muhombe K, Tsu V, Herdman C. Screening and management of precancerous lesions to prevent cervical cancer in low-resource settings. Asian Pac J Cancer Prev 2003; 4:277-280.
13. Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001; 15:2157-2164.
14. Omar T, Schwartz S, Hanrahan C, Modisenyane T, Tshabangu N, Golub JE, et al. Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: A prospective cohort. AIDS 2011; 25:87-94.
15. RobinsonW3rd. Invasive and preinvasive cervical neoplasia in human immunodeficiency virus-infected women. Semin Oncol 2000; 27:463-470.
16. Barillari G, Sgadari C, Toschi E, Monini P, Ensoli B. HIV protease inhibitors as new treatment options for Kaposi's sarcoma. Drug Resist Updat 2003; 6:173-181.
17. Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol 2003; 4:537-547.
18. Monini P, Sgadari C, Barillari G, Ensoli B. HIV protease inhibitors: Antiretroviral agents with anti-inflammatory, antiangiogenic and antitumour activity. J Antimicrob Chemother 2003; 51:207-211.
19. Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B. Antitumour effects of antiretroviral therapy. Nature Rev Cancer 2004; 4:861-875.
20. Sgadari C, Bacigalupo I, Barillari G, Ensoli B. Pharmacological management of Kaposi's sarcoma. Expert Opin Pharmacother 2011; 12:1669-1690.
21. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, et al. HIV protease inhibitors are potent antiangiogenic molecules and promote regression of Kaposi sarcoma. Nature Med 2002; 8:225-232.
22. Esposito V, Palescandolo E, Spugnini EP, Montesarchio V, De Luca A, Cardillo I, et al. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma. Clin Cancer Res 2006; 12:2634-2639.
23. Spugnini EP, Esposito V, Groeger AM, Cassandro R, Onori N, Chirianni A, et al. Effects of indinavir in a preliminary phase I study on dogs with stage III slenic hemangiosarcoma. In Vivo 2006; 20:125-127.
24. Kumar S, Bryant CS, Chamala S, Qazi A, Seward S, Pal J, et al. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Molec Cancer 2009; 8:26.
25. Toschi E, Sgadari C, Malavasi L, Bacigalupo I, Chiozzini C, Carlei D, et al. Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases. Int J Cancer 2011; 128:82-93.
26. Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: Back to the future? Lancet Oncol 2009; 10:61-71.
27. Gaedicke S, Firat-Geier E, Constantiniu O, Lucchiari-Hartz M, Freudenberg M, Galanos C, et al. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: Induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 2002; 62:6901-6908.
28. Kraus M, Malenke E, Gogel J, Müller H, Rückrich T, Overkleeft H, et al. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. Mol Cancer Ther 2008; 7:1940-1948.
29. Piccinini M, Rinaudo MT, Anselmino A, Buccinnà B, Ramondetti C, Dematteis A, et al. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antivir Ther 2005; 10:215-223.
30. Monini P, Sgadari C, Grosso MG, Bellino S, Di Biagio A, Toschi E, et al. Clinical course of classic Kaposi's sarcoma in HIVnegative patients treated with the HIV protease inhibitor indinavir. AIDS 2009; 23:534-538.
31. Wooldridge TR, Laimins LA. Regulation of human papillomavirus type 31 gene expression during the differentiationdependent life cycle through histone modifications and transcription factor binding. Virology 2008; 374:371-380.
32. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microb Mol Biol Rev 2004; 68:362-372.
33. Apraiz A, Idkowiak-Baldys JK, Boyano MD, Pérez-Yarza G, Hannun YA, Asumendi A. Evaluation of bioactive sphingolipids in 4-HPR-resistant leukemia cells. BMC Cancer 2011; 11: 477.
34. Nakano H, Omura S. Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine. J Antimicrob 2009; 62:17-26.
35. Justesen US. Protease inhibitor plasma concentrations in HIV antiretroviral therapy. Dan Med Bull 2008; 55:165-185.
36. Maruo T, Yoshida S, Samoto T, Tateiwa Y, Peng X, Takeuchi S, et al. Factors regulating SCC antigen expression in squamous cell carcinoma of the uterine cervix. Tumour Biol 1998; 19: 494-504.
37. Liuzzi GM, Mastroianni CM, Latronico T, Mengoni F, Fasano A, Lichtner M, et al. Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain 2004; 127:398-407.
38. De Barros S, Zakaroff-Girard A, Lafontan M, Galitzky J, Bourlier V. Inhibition of human preadipocyte proteasomal activity by HIV protease inhibitors or specific inhibitor lactacystin leads to a defect in adipogenesis, which involves matrix metalloproteinase-9.. J Pharmacol Exp Ther 2007; 320:291-299.
39. da Silva Cardeal LB, Brohem CA, Corrêa TC, Winnischofer SM, Nakano F, Boccardo E, et al. Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence. Biochem Cell Biol 2006; 84:713-719.
40. Hampson L, Kitchener HC, Hampson IN. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Antivir Ther 2006; 11:813-825.
41. Iwasaki M, Nishikawa A, Fujimoto T, Akutagawa N, Manase K, Endo T, et al. Antiinvasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines. Gynecol Oncol 2002; 85:103-107.
42. Kato Y, Yamashita T, Ishikawa M. Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells. Oncol Rep 2002; 9:565-569.
43. Lesnikova I, Lidang M, Hamilton-Dutoit S, Koch J. Rapid, sensitive, type specific PCR detection of the E7 region of human papillomavirus type 16 and 18 from paraffin embedded sections of cervical carcinoma. Infect Agent Cancer 2010; 5:2.
44. Ma Z, Chang MJ, Shah RC, Benveniste EN. Interferon-gammaactivated STAT-1alpha suppresses MMP-9 gene transcription by sequestration of the coactivators CBP/p300. J Leukoc Biol 2005; 78:515-523.
45. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004; 114:623-633.
46. Hougardy BM, Reesink-Peters N, van den Heuvel FA, ten Hoor KA, Hollema H, de Vries EG, et al. A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants. Int J Cancer 2008; 123:1457-1465.
47. Chen D, Frezza M, Schmitt S, Kanwar J, P Dou Q. Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr Cancer Drug Targets 2011; 11:239-253.
48. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2011; 278:16-27.
49. Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004; 48:411-424.
50. Hong-Brown LQ, Brown CR, Lang CH. Indinavir impairs protein synthesis and phosphorylations of MAPKs in mouse C2C12 myocytes. Am J Physiol Cell Physiol 2004; 287:C1482-C1492.
51. Gupta AK, Cerniglia GJ, Mick R, McKenna G, Muschel RJ. HIV protease inhibitors block Akt signalling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005; 65:8256-8265.
52. Au Yeung CL, Tsang TY, Yau PL, Kwok TT. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase- type plasminogen activator pathway. Oncogene 2011; 30:2401-2410.
53. Sánchez-Hernández PE, Ramirez-Duenas MG, Albarran-Somoza B, García-Iglesias T, del Toro-Arreola A, Franco-Topete R, et al. Protease-activated receptor-2 (PAR-2) in cervical cancer proliferation. Gynecol Oncol 2008; 108:19-26.
54. Jones JL, Hanson DL, Dworkin MS, Ward JW, Jaffe HW. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group. J Acquir Immune Defic Syndr 1999; 21 (Suppl 1):17.
55. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-432.
56. Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: Changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006; 19:14-19.
57. Dal Maso L, Polesel J, Serraino D, Lise M, Piselli P, Falcini F, et al. Pattern of cancer risk in persons with AIDS in Italy in the HAART era. Br J Cancer 2009; 100:840-847.